Reports depicting the clinical pictures and profiles of patients colonized or infected by ESBL-producing Enterobacteriaceae isolates and admitted to hospital have mainly been published from the United States, Canada or Israel but are rather limited in Europe [ 8, 9, 12].
By focusing on practitioners in industry, this work complements current surveys in optimisation that have mainly focused on published literature.
Most previous published studies have mainly focused on only one of these outcome measures [ 4, 6, 25].
In this review, we have mainly focused on the already published data from our laboratory pertaining to the effect of methanol extract of pericarp of pomegranate (PME) and have compared it with other relevant literatures on Punica.
The majority of published studies have mainly been based on imperfect reference standards such as assessing the change in tumour size over a follow-up of 6 – 24 months [ 3, 10– 10].
Individual current cost data on HER2-positive BC with CNS metastases are limited and published series have mainly reported costs of advanced BC, regardless of their subtype [ 15- 17].
While ipilimumab is effective in metastatic cutaneous melanoma 75, it did not yet appear to be superior to chemotherapy regimens in MUM, possibly because published data have mainly been generated from expanded access programs in non-first-line situations.
The review articles published thus far have mainly focused on multiple environmental and agronomic applications of biochar, including carbon sequestration, soil improvement, environmental remediation, etc.
The CAM meta-ethnographies published so far have mainly focused on one treatment modality or on one indication.
1, 2 The detrimental impact of hypoglycemia is highlighted in a number of recently published studies, which have mainly focused on the effects of severe hypoglycemic events.
